{"id":780948,"date":"2023-08-30T09:41:25","date_gmt":"2023-08-30T13:41:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-reports-results-for-fiscal-quarter-ended-june-30-2023-and-business-update\/"},"modified":"2023-08-30T09:41:25","modified_gmt":"2023-08-30T13:41:25","slug":"portage-biotech-reports-results-for-fiscal-quarter-ended-june-30-2023-and-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-reports-results-for-fiscal-quarter-ended-june-30-2023-and-business-update\/","title":{"rendered":"Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update"},"content":{"rendered":"

\nCompany focused on accelerating clinical programs for PORT-2, PORT-6, and PORT-7
\n<\/h2>\n
\n

WESTPORT, Conn., Aug. 30, 2023 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended June 30, 2023.<\/p>\n

\u201cIn recent weeks we have continued to build on the favorable interim data and early evidence of single agent activity from the Phase 1\/2 trial of our lead program, PORT-2, presented at the 2023 annual meeting of the American Society for Clinical Oncology (ASCO) in June, and our near-term focus is defining the recommended Phase 2 dose,\u201d said Dr. Ian Walters, Chief Executive Officer, and Chairman of Portage Biotech. \u201cWe have transferred sponsorship of the clinical trial from the academic sponsor to Portage and amended the protocol to include a higher dose level. As a result, we are significantly expanding our clinical footprint to 17 planned sites with the goal of speeding up patient accrual by adding 15 additional sites, in the US, UK, and Spain. We expect final data from the Phase 1 portion of the trial in the first calendar quarter of 2024.\u201d<\/p>\n

\u201cIn July, we announced the dosing of the first patient in our adaptive Phase 1a\/1b trial, ADPORT-601 evaluating PORT-6, our adenosine 2A receptor (A2A) antagonist candidate, and have completed enrollment in the low dose cohort,\u201d continued Dr. Walters. \u201cAs with our PORT-2 program, we are keenly focused on activating quality clinical sites and establishing a broad footprint to support patient accrual. Several sites including MD Anderson Cancer Center, UCSF Comprehensive Cancer Center, The USC Norris Comprehensive Cancer Center, Thomas Jefferson University, Virginia Cancer Specialists, Norton Cancer Institute, Washington University School of Medicine, and Sarah Canon Research Institute are currently participating. We are also in the process of amending the trial to include PORT-7, our adenosine 2B receptor (A2B) antagonist candidate, dose escalation and combinations with PORT-6 arms. We are confident in our clinical programs and development approach and are excited to see the data generated by all three assets.\u201d<\/p>\n

\n Company Highlights <\/strong>\n <\/p>\n